Author Interviews, Gastrointestinal Disease / 11.02.2025

MedicalResearch.com Interview with: [caption id="attachment_66492" align="alignleft" width="144"]Arun B. Jesudian, MDAssociate Professor of Clinical Medicine Medicine  Weill Cornell Medical Center Transplant hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center Dr. Jesudian[/caption] Arun B. Jesudian, MD Associate Professor of Clinical Medicine Medicine Weill Cornell Medical Center Transplant hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center MedicalResearch.com: What is the background for this study? Response: In recent years, the demand for gastroenterologists continues to increase due to an aging population, increase in the prevalence of gastrointestinal and hepatology diseases, updates in screening and surveillance recommendations, and advances in therapeutic techniques. In this study, we set out to examine geographic distributions of gastroenterologists in the United States. MedicalResearch.com: What are the main findings? Response:  We found that on a national level, over 80% of the population lives within 25 miles of the closest gastroenterologist. However, 2,183 (69%) of the US counties do not have a practicing gastroenterologist, and 454 of the 1,167 metropolitan counties in the US do not have a gastroenterologist. Additionally, gastroenterologists in non-metropolitan counties tend to be older, with almost a third over the age of 65.
Gastrointestinal Disease / 01.10.2024

Editors' note:  Be sure to follow up with recommended colonoscopy examinations.  If you are having bowel or rectal symptoms,  consult your health care provider before relying on home remedies.  When you're in the grip of hemorrhoid pain, relief can't come soon enough. It’s a common misconception that hemorrhoids are untreatable. However, there are numerous strategies you can employ to prevent and manage hemorrhoids, offering a glimmer of hope and empowerment in your journey to wellness. Hemorrhoids, depending on their position, can cause cases of bleeding, itching, soreness, or pain. Internal hemorrhoids lead to painless bleeding, while external hemorrhoids lead to pain. Below are the five tips that can assist in reducing hemorrhoid discomfort.

Author Interviews, Colon Cancer, Gastrointestinal Disease, Immunotherapy / 04.06.2024

MedicalResearch.com Interview with: [caption id="attachment_61859" align="alignleft" width="130"]Steven H. Itzkowitz, MD, FACP, FACG, AGAFProfessor of Medicine and Oncological Sciences Director of the GI Fellowship Program Icahn School of Medicine at Mount Sinai Dr. Itzkowitz[/caption] Steven H. Itzkowitz, MD, FACP, FACG, AGAF Professor of Medicine and Oncological Sciences Director of the GI Fellowship Program Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: This study looked at patients with inflammatory bowel disease (IBD) who had a history of cancer in the past 5 years and asked whether the medications they received for their IBD might have affected their rates of getting future cancer (new or recurrent cancers). Because many of the medicines that are used to treat IBD can affect the immune system in various ways, there has been concern that the medicines might predispose to subsequent cancers. We found that patients who received immunosuppressive medications had a numerically increased risk of subsequent cancer, this was not statistically higher than those who had not been exposed to these medications. While previous studies have looked at this question retrospectively, this is the first report that analyzed this issue prospectively using individuals from the United States.  Moreover, this study represents a multi-institutional collaboration among gastroenterologists at most of the major NYC healthcare systems.
Author Interviews, Heart Disease, JAMA, Pediatrics, Surgical Research / 25.11.2020

MedicalResearch.com Interview with: [caption id="attachment_56023" align="alignleft" width="200"]Michael R. Flaherty, DO Attending, Pediatric Critical Care Medicine Co-Director, Trauma and Injury Prevention Outreach Program, MGH Instructor in Pediatrics, Harvard Medical School Boston, MA 02114 Dr. Flaherty[/caption] Michael R. Flaherty, DO Attending, Pediatric Critical Care Medicine Co-Director, Trauma and Injury Prevention Outreach Program, MGH Instructor in Pediatrics, Harvard Medical School Boston, MA 02114 MedicalResearch.com: What is the background for this study? What are the main findings?   Response: This study was a joint collaboration between Massachusetts General Hospital and Boston Children’s Hospital. The Consumer Product Safety Commission (CPSC) found an increasing incidence of rare earth magnet ingestions by children causing serious injury; Injuries are particularly serious when a child ingests two of these small magnets, or a magnet with another metal object – this can lead to bowel walls becoming attached and kinked, leading to catastrophic bowel injury and/or death. The Consumer Product Safety Commission initiated campaigns to limit sales in 2012 with voluntary recalls and safety standards, as well as public awareness campaigns, legislative advocacy, and lawsuits. In October 2014, the CPSC published their final rule, “Safety Standard for Magnet Sets,” which prohibited the sale of magnets based on a pre-specified size and power scale, essentially eliminating the ability to sell SREMs. This rule was appealed by largest manufacturer of these magnets, Zen Magnets, LLC., and in November 2016 this rule was legally reversed by the U.S. Court of Appeals Tenth Circuit resulting in a resurgence of these magnets on the market.
Author Interviews, Cancer Research, Colon Cancer / 05.11.2020

MedicalResearch.com Interview with: [caption id="attachment_55847" align="alignleft" width="200"]Hisham Hussan, MD, FACG The Ohio State University Wexner Medical Center Dr. Hussan[/caption] Hisham Hussan, MD, FACG The Ohio State University Wexner Medical Center  MedicalResearch.com: What is the background for this study? Response: Early-onset colorectal cancer (i.e., CRC diagnosed before 50 years of age) is predicted to rise to 10.9% of all colon and 22.9% of all rectal cancers by 2030. Some studies identified an association between early-onset CRC and obesity. By contrast, other studies found a similar body mass index (BMI) between adults with and without early-onset CRC. These conflicting findings are possibly due to weight loss from colorectal cancer that may obscure its relation to obesity.
Author Interviews, COVID -19 Coronavirus, Gastrointestinal Disease / 01.11.2020

MedicalResearch.com Interview with: [caption id="attachment_55810" align="alignleft" width="190"]Darbaz Adna​n, MBChB Lab Research Assistant Department of Internal Medicine - Section of Gastroenterology Rush University Medical Center Chicago, Illinois 60612 Dr. Adnan[/caption] Darbaz Adna​n, MBChB Lab Research Assistant Department of Internal Medicine - Section of Gastroenterology Rush University Medical Center Chicago, Illinois 60612 MedicalResearch.com: What is the background for this study? Response: - We have conducted a large study of over 1000 patients at a major COVID-19 response center in Chicago at Rush University Medical Center, to assess for the frequency of initial GI symptoms (diarrhea, vomiting, abdominal pain) and evaluate whether these symptoms in adult COVID-19 positive could predict the disease course. Overall, 22.4% of our patients reported at least one GI symptom at the onset of their infection, with nausea/vomiting being the most common complaint. GI symptoms in COVID-19 patients were associated with worse outcomes.
Annals Internal Medicine, Author Interviews, Esophageal, Gastrointestinal Disease / 20.10.2020

MedicalResearch.com Interview with: 加藤元嗣　Mototsugu KATO MD PhD 院長  独立行政法人国立病院機構函館病院 Director, National Hospital Organization Hakodate National Hospita MedicalResearch.com: What is the background for this study? Response: The primary goal of upper gastrointestinal (GI) endoscopic examination is to detect neoplastic lesions in the pharynx, esophagus, and stomach. However, early-stage lesions may frequently be overlooked by conventional white light endoscopy. Since the recent launch of image-enhanced endoscopy, many studies have evaluated its efficacy in diagnosing upper GI neoplasms as well. Linked color imaging (LCI )emphasizes the difference in color to make it easier to detect neoplastic lesions. The aim of this trial is to compare the performance of LCI with white light imaging in detecting upper GI tract neoplastic lesions. 
Author Interviews, Gastrointestinal Disease, Nutrition / 30.09.2020

MedicalResearch.com Interview with: David C. Montrose, Ph.D. Assistant Professor Department of Pathology Renaissance School of Medicine Stony Brook Cancer Center Stony Brook University MedicalResearch.com: What is the background for this study? What are the main findings? Response: Rates of inflammatory bowel disease (IBD) have been increasing worldwide. In parallel with this, fructose consumption has increased. This study demonstrates that feeding high levels of fructose worsens intestinal inflammation in mouse models of inflammatory bowel disease (IBD). This fructose-induced worsening of disease is mediated through effects on gut bacteria.
Author Interviews, COVID -19 Coronavirus, Gastrointestinal Disease / 27.08.2020

MedicalResearch.com Interview with: [caption id="attachment_55240" align="alignleft" width="179"]Dr. Arvind J. Trindade, MD Director of Endoscopy Long Island Jewish Medical Center Division of Gastroenterology, Zucker School of Medicine Hofstra/Northwell, Northwell Health System New Hyde Park, NY Dr. Trindade[/caption] Dr. Arvind J. Trindade, MD Director of Endoscopy Long Island Jewish Medical Center Associate professor at Feinstein Institutes for Medical Research Division of Gastroenterology, Zucker School of Medicine Hofstra/Northwell, Northwell Health System New Hyde Park, NY MedicalResearch.com: What is the background for this study? Response: Although most patients with COVID-19 present with respiratory symptoms, gastrointestinal (GI) symptoms have also been reported in up to 25% of patients. Some case reports have shown acute pancreatitis as the initial presentation in patients with COVID-19, however the literature supporting this is limited. Our study aimed to report the point prevalence, risk factors, and outcomes of hospitalized patients with COVID-19 presenting with acute pancreatitis in a large health system and to compare outcomes of pancreatitis in patients without COVID-19.
Author Interviews, Gastrointestinal Disease, JAMA, Outcomes & Safety, Surgical Research / 31.07.2019

MedicalResearch.com Interview with: [caption id="attachment_50510" align="alignleft" width="160"]Ninh T. Nguyen, MD Department of Surgery University of California Irvine Medical Center Orange, California Dr. Nguyen[/caption] Ninh T. Nguyen, MD Department of Surgery University of California Irvine Medical Center Orange, California MedicalResearch.com: What is the background for this study? Response: The US World & News Report publishes each year on top ranked hospitals for specific specialties. These ratings are promoted nationally and used by patients and physicians in making decisions about where to receive care for challenging conditions or common elective procedures. Bariatric, colorectal and hiatal hernia procedures are common gastrointestinal operations being performed at most hospitals. Seeking care for these operations specifically at top 50 ranked hospitals can pose significant logistic and financial constraints for most patients. The objective of this study was to determine whether top ranked hospitals (RHs) in Gastroenterology & GI Surgery (GGS) have improved outcomes for advanced laparoscopic abdominal surgery compared to non-ranked hospitals (NRHs).
Author Interviews, Gastrointestinal Disease / 10.06.2019

MedicalResearch.com Interview with: [caption id="attachment_49661" align="alignleft" width="142"]William D. Chey, M.D., F.A.C.G. Director, Division of Gastroenterology Michigan Medicine Gastroenterology Clinic Ann Arbor, Michigan Dr. Chey[/caption] William D. Chey, M.D., F.A.C.G. Director, Division of Gastroenterology Michigan Medicine Gastroenterology Clinic Ann Arbor, Michigan MedicalResearch: What is the background for this study? Would you tell us what is meant by Functional Dyspepsia? Response: Functional dyspepsia (FD or meal-triggered indigestion) is a very common disorder affecting 11 percent - 29.2 percent of the world’s population, making it comparable in prevalence to Irritable Bowel Syndrome (IBS). However, unlike IBS, there is no FDA approved product to treat FD. Sufferers are often treated off-label with prescribed proton pump inhibitors (PPIs), histamine type-2 receptor antagonists (H2RAs), antidepressants, and prokinetics. While offering relief to a portion of FD patients, some of these have been associated with adverse events. Functional dyspepsia can have a negative effect on workplace attendance and productivity, with associated costs estimated in excess of $18 billion annually. In functional dyspepsia, which is typically recurring, meal-triggered indigestion with no known organic cause, the normal function and sensation of the stomach and intestines are altered. FD is accompanied by symptoms such as epigastric pain or discomfort, epigastric burning, postprandial fullness, inability to finish a normal sized meal, heaviness, pressure, bloating in the upper abdomen, nausea, and belching. When doctors diagnose FD, they often identify patients as those who have these symptoms for at least three months, with symptom onset six months previously. Caraway oil and peppermint oil have a history of helping some patients with functional dyspepsia. In multiple clinical studies, the combination of caraway oil and peppermint oil has been shown to manage FD and its accompanying symptoms, such as reducing the intensity of epigastric pain, pain frequency, dyspeptic discomfort, and the intensity of sensations of pressure, abdominal heaviness and fullness significantly better than control
Author Interviews, Gastrointestinal Disease, JAMA, Microbiome / 16.01.2019

MedicalResearch.com Interview with: [caption id="attachment_46964" align="alignleft" width="200"]Samuel P. Costello MBBS Inflammatory Bowel Disease Service, Department of Gastroenterology, The Queen Elizabeth Hospital Australia Dr. Costello[/caption] Samuel P. Costello MBBS Inflammatory Bowel Disease Service, Department of Gastroenterology The Queen Elizabeth Hospital Australia MedicalResearch.com: What is the background for this study? Response: Ulcerative colitis (UC) is an inflammatory bowel disease that has high rates of persistent or relapsing symptoms despite available therapies. Many of these therapies also have the potential for unacceptable side effects including allergy, intolerance, serious infection and malignancy due to long-term immunosuppression. It is for these reasons that new therapies for Ulcerative colitis are required; particularly therapies that target novel pathways and are not immune suppressing.
Author Interviews, Gastrointestinal Disease / 16.01.2019

MedicalResearch.com Interview with: [caption id="attachment_46969" align="alignleft" width="200"]Dr. Peter Stanich MD Assistant Professor of Gastroenterology, Hepatology and Nutrition The Ohio State University Wexner Medical Center and College of Medicine Dr. Stanich[/caption] Dr. Peter Stanich MD Assistant Professor of Gastroenterology, Hepatology and Nutrition The Ohio State University Wexner Medical Center and College of Medicine MedicalResearch.com: What is the background for this study? What are the main findings?  Response: We knew of toilet stools from popular culture and wanted to study this in a scientific way. This is something that patients, family and friends always ask about and we wanted to start the process of assessing it more rigorously to see if they are beneficial. 
Author Interviews, Gastrointestinal Disease, Infections / 08.03.2018

MedicalResearch.com Interview with: [caption id="attachment_40440" align="alignleft" width="120"]Esther Bullitt, Ph.D. Associate Professor Dept. of Physiology & Biophysics Boston University School of Medicine Boston, MA  02118-2526 Dr. Bullitt[/caption] Esther Bullitt, Ph.D. Associate Professor Dept. of Physiology & Biophysics Boston University School of Medicine Boston, MA  02118-2526  MedicalResearch.com: What is the background for this study? Response:      We know that saliva has properties that allow us to swallow easily, and to help prevent gum disease and infections in the mouth. But is that really the only use for the 1-2 liters (1-2 quarts) of saliva we produce every day?  We decided to test whether a component of saliva, Histatin-5, can help prevent diarrheal disease (Traveler’s Diarrhea by Enterotoxigenic Escherichia coli (ETEC)) that is caused by bacteria commonly found in contaminated food and water. ETEC are bacteria that have hundreds of thin hair-like fibers on their surface, called pili. These bacteria bind specifically to the surface of the gut using these pili, and the bacteria need to stay bound long enough to initiate disease. Studies by Mike Levine’s group in the 1970’s showed that pili are necessary for enterotoxigenic Escherichia coli (ETEC) to cause disease. No adhesion, no disease. One aid to remaining bound is the unwinding and rewinding of the pili. These helical fibers can unwind up to 8 times their original length, acting as shock absorbers during fluid flow.  
Author Interviews, Gastrointestinal Disease, Pain Research / 28.11.2017

MedicalResearch.com Interview with: [caption id="attachment_38572" align="alignleft" width="142"]Charles Melbern (Mel) Wilcox, MD, MSPH Director of the division of Gastroenterology and Hepatology University of Alabama-Birmingham Dr. Wilcox[/caption] Charles Melbern (Mel) Wilcox, MD, MSPH Director of the division of Gastroenterology and Hepatology University of Alabama-Birmingham  MedicalResearch.com: What is the background for this survey? What are the main findings? Response: Nearly every person experiences pain at some point in their life – for many, the pain is acute and occasional, but for others, the pain is chronic and can be debilitating. Research shows that more than 25.3 million Americans suffer from daily pain and, every year, consumers purchase more than $20 billion per year on over-the-counter (OTC) pain medicines. In my work with the American Gastroenterological Association, we set out to explore the behaviors, beliefs, and misunderstandings that Americans have when it comes to OTC pain medicines. We surveyed 1,015 U.S. adults and 251 gastroenterologists to gain insight on how they were approaching pain management and OTC pain medicine use. The survey found that Americans are routinely ignoring OTC pain medicine labels and are not consulting their health-care professionals about their pain before taking OTC pain medicines. As a direct result, gastroenterologists are noticing their patients experiencing complications and unintentional overdose symptoms. They see an average of 90 overdose cases each year, about two a week, due to OTC pain medicine overdose. Ninety percent of gastroenterologists believe their patients require more and better education on how to use OTC pain medicine safely. They find that patients are not fully understanding the harms associated with taking too much. When asked why patients take more than the recommended dose, Americans say that they are confident in their ability to manage their medication (32 percent) or they wanted to feel better faster, mistakenly thinking more medicine would be the solution (73 percent).
Author Interviews, Gastrointestinal Disease, Pharmacology / 15.10.2017

MedicalResearch.com Interview with: [caption id="attachment_37464" align="alignleft" width="139"]Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.S.G.E. Professor of Medicine and Chief of the USA Gastroenterology Division Director, Motility and Physiology Service University of South Alabama Mobile, Alabama Dr. Cash[/caption] Brooks D. Cash, M.D., A.G.A.F., F.A.C.G., F.A.S.G.E. Professor of Medicine and Chief of the USA Gastroenterology Division Director, Motility and Physiology Service University of South Alabama Mobile, Alabama  MedicalResearch.com: What is the background for this study? Response: Irritable Bowel Syndrome (IBS) among patients with IBS-M (mixed diarrhea and constipation) is a challenging and difficult to diagnose and treat sub-type of IBS. Patients with IBS-M represent a dissatisfied group of IBS patients due to the lack of proven therapies. It is an area of high unmet medical need. Among adult patients with IBS, a sizeable proportion suffers from IBS-M with prevalence rates estimated to be between 44 to 66 percent of IBS sufferers[1],[2],[3]. IBS-M patients carry a heavy burden, characterized by bouts of constipation interrupted by diarrhea and vice versa. Physicians find IBS-M challenging to manage because of the difficulty in avoiding ‘overshoots’ when diarrhea management can turn into constipation and vice versa.[4] 
Author Interviews, Gastrointestinal Disease, Microbiome / 28.07.2017

MedicalResearch.com Interview with: [caption id="attachment_36197" align="alignleft" width="126"]Eric I. Benchimol, MD, PhD, FRCPC Associate Professor of Pediatrics and Epidemiology, University of Ottawa Division of Gastroenterology, Hepatology and Nutrition Children's Hospital of Eastern Ontario Ottawa, ON Canada Dr. Benchimol[/caption] Eric I. Benchimol, MD, PhD, FRCPC Associate Professor of Pediatrics and Epidemiology, University of Ottawa Division of Gastroenterology, Hepatology and Nutrition Children's Hospital of Eastern Ontario Ottawa, ON Canada MedicalResearch.com: What is the background for this study? What are the main findings? Response: We found that living in a rural household (compared to urban households) was protective against developing inflammatory bowel disease (IBD). People living in a rural household were around 10% less likely to get IBD (Crohn’s disease and ulcerative colitis). While our finding that IBD was more common in people living in urban households was similar to other studies from around the world, there were a number of new, interesting findings:
  1. Living in a rural household was most protective against pediatric-onset IBD. In fact, it was not protective in IBD with onset between ages 18-39, 40-64, or 65 and older at diagnosis.
  2. Living in a rural household in the first 5 years of life was highly protective against IBD later in life.
These findings indicate the importance of early life environmental exposures in the subsequent development of IBD. This effect has been seen in the inflammatory bowel disease literature when examining other environmental risk factors, particularly early-life antibiotic use and air pollution. These risk factors seem to have the strongest effect of increasing the risk of childhood-onset IBD, and not adult-onset disease.
Author Interviews, Pharmacology / 05.06.2017

MedicalResearch.com Interview with: [caption id="attachment_35036" align="alignleft" width="142"]William D. Chey, M.D., F.A.C.G.</strong> Director, Division of Gastroenterology Michigan Medicine Gastroenterology Clinic Ann Arbor, Michigan Dr. Chey[/caption] William D. Chey, M.D., F.A.C.G. Director, Division of Gastroenterology Michigan Medicine Gastroenterology Clinic Ann Arbor, Michigan MedicalResearch.com: What is the background for this study? Response: Functional Dyspepsia (FD), which is persistent or recurring upper abdominal pain, burning, or fullness with no known organic cause, is a relatively common and often frustrating condition. The precise causes of this condition are unknown, but problems with mild inflammation, leakiness of the lining of the gut, overactive sensation, and abnormal contractions of the upper digestive tract are thought to play a role in many patients. FD often reoccurs over time and it is an area of high unmet medical need. Functional Dyspepsia can have a significant impact on quality of life. Currently, off-label medications are used to treat FD, as there is no U.S. Food and Drug Administration (FDA)-approved pharmaceutical product for the condition. An estimated 62 percent of FD patients suffer from Epigastric Pain Syndrome (EPS, which is epigastric pain or burning), while an estimated 73 percent of FD patients suffer from Postprandial Distress Syndrome (PDS, which is early fullness, pressure and heaviness); 35 percent suffer from both. In this study, we compared the efficacy of a unique encapsulated formulation of caraway oil and l-Menthol, the primary component in peppermint oil), (COLM-SST) to placebo in patients taking their usual Functional Dyspepsia medications. Caraway oil contains carvone and d-limonene, which have gastroprotective and prokinetic effects; l-Menthol has anti-inflammatory, prokinetic, analgesic and gastroprotective effects.
Author Interviews, Gastrointestinal Disease, Kidney Stones / 31.10.2016

MedicalResearch.com Interview with: [caption id="attachment_29289" align="alignleft" width="175"]Dr. Hatim A. Hassan Section of Nephrology, Department of Medicine The University of Chicago Chicago, IL 60637 Dr. Hatim A. Hassan[/caption] Dr. Hatim A. Hassan MD PhD Section of Nephrology, Department of Medicine The University of Chicago Chicago, IL 60637 MedicalResearch.com: What is the background for this study? Response: Nephrolithiasis is the second most prevalent kidney disease in USA after hypertension, with a rising prevalence and complications including advanced chronic kidney disease (CKD) and end stage renal disease (ESRD). It remains a major source of patient discomfort and disability, lost working days, and health-care expenditure, with an annual economic cost approaching $10 billion. Hyperoxaluria is a major risk factor for kidney stones (KS), and 70-80% of KS are composed of calcium oxalate. Urinary oxalate is an important determinant of supersaturation, and the risk for stone formation is affected by small increases in urine oxalate. Oxalate is a metabolic end product that cannot be further metabolized and is highly toxic. The mammalian intestine plays a crucial role in oxalate homeostasis, by regulating the amount of absorbed dietary oxalate and providing an avenue for enteric oxalate excretion. Anion exchanger SLC26A6 (A6)-mediated intestinal oxalate secretion plays a critical role in preventing hyperoxaluria and calcium oxalate kidney stones (COKS). Inflammatory bowel disease patients have a significantly increased risk of kidney stones due to the associated enteric hyperoxaluria. Obesity is a risk factor for KS and obese stone formers often have mild to moderate hyperoxaluria. Hyperoxaluria is also emerging as a major complication (developing in > 50% of patients) of bariatric surgery for obesity. With the rising prevalence of obesity and increased utilization of bariatric surgery, it is expected that the incidence of hyperoxaluria and related COKS (including the associated cost burden) will continue to increase at a significant rate. Primary hyperoxaluria (PH) is an inherited disease in which there is endogenous oxalate overproduction, which leads to recurrent KS and/or progressive nephrocalcinosis, ESRD, as well as significant hyperoxalemia, systemic oxalosis and premature death. Systemic deposition of calcium oxalate (oxalosis) leads to bone disease, cardiac arrhythmias, cardiomyopathy, skin ulcers, erythropoietin refractory anemia, and digital gangrene. The only treatment known to fully correct the underlying metabolic defect is liver transplantation or combined kidney-liver transplantation once ESRD develops. In addition, significant hyperoxalemia is also seen in ESRD. Cardiovascular diseases are the leading cause of morbidity and mortality in ESRD patients, and a recent report raised the possibility that the ESRD-associated hyperoxalemia might contribute to this increased risk. Lowering serum oxalate might improve cardiovascular outcomes in ESRD patients if these findings are confirmed. Unfortunately, there is currently no specific therapy that effectively lowers urine and/or plasma oxalate level(s), and the risk of recurrent COKS, nephrocalcinosis, oxalate nephropathy, ESRD, & systemic oxalosis remains substantial in the absence of treatment.
Author Interviews, Gastrointestinal Disease / 22.10.2016

MedicalResearch.com Interview with: [caption id="attachment_29078" align="alignleft" width="142"]Christopher V. Almario, MD, MSHPM</strong> Assistant Professor of Medicine Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center Cedars-Sinai Center for Outcomes Research and Education Los Angeles, CA Dr. Christopher V. Almario[/caption] Christopher V. Almario, MD, MSHPM Assistant Professor of Medicine Division of Digestive and Liver Diseases, Cedars-Sinai Medical Center Cedars-Sinai Center for Outcomes Research and Education Los Angeles, CA MedicalResearch.com: What is the background for this study? Response: Recent drug approvals have increased the availability of biologic therapies for inflammatory bowel disease (IBD). However, the growing number of biologics has also made it more difficult for both patients and healthcare providers to navigate treatment options and to ultimately choose the most appropriate therapy. In this study, we wanted to examine patient decision-making surrounding IBD biologic therapies using conjoint analysis, which is a form of tradeoff analysis that determines how respondents make complex decisions by presenting them with competing product profiles. Here, we quantified the relative importance of 9 biologic therapy attributes (e.g., how the medicine works, how the medicine is received, long-term effectiveness, side-effect profile, etc.) in the decision-making process.
Author Interviews, Gastrointestinal Disease, Nutrition, Science / 29.09.2016

MedicalResearch.com Interview with: [caption id="attachment_28438" align="alignleft" width="180"]Distinguished Professor Kourosh Kalantar-zadeh RMIT's School of Engineering Australia Prof. Kourosh Kalantar-Zadeh[/caption] Distinguished Professor Kourosh Kalantar-Zadeh RMIT's School of Engineering Australia MedicalResearch.com: What is the background for this study? What are the main findings? 1- The development of "swallow-able gas sensor capsules". This was the final test on animals and focused on the measurement of a food supplement (cinnamon) to show the extraordinary capability of this noninvasive tool that will revolutionise the future of Gastroenterology and Food Sciences 2- That cinnamon can improve the health of the stomach, and hence our overall health, by adjusting the acidity and enzymatic secretion in the stomach. So the good effect of cinnamon is not just a grandparent old advice - It is real.
Thank you for visiting MedicalResearch.com Senior Editor, Marie Benz MD. For more information please email: info@MedicalResearch.com

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.